COVID-19’s Impact on Pharma Continues into 2022

For the second year in a row, COVID-19 is the most pressing topic in the pharmaceutical industry. In an article by AIS Health, industry leaders project the landscape of pharma in 2022. A key trend that Mike Delone of Deloitte Consulting LLP predicts will continue this year is the increasing digitization at every level of the industry. In addition, he expects that companies will further take advantage of artificial intelligence (AI).

According to Delone, “In the year ahead, I suspect we will see more companies integrate AI more holistically into all processes — from preliminary research to clinical trials to manufacturing and supply chain to commercialization and enabling functions. The combination of human intelligence and AI will likely also continue to influence how companies react and respond to health care professionals and the patients they serve.”

Read insights from several other industry experts by clicking here.

(Source: MMIT Network, January 6^th, 2022)